Interferons at age 50: past, current and future impact on biomedicine - Wikidata - wikimedia - TriplyDB

Interferons at age 50: past, current and future impact on biomedicine

Interferons at age 50: past, current and future impact on biomedicine

http://www.wikidata.org/entity/Q28259312

about

Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types Exploiting tumor epigenetics to improve oncolytic virotherapy Overview of the biology of type I interferons Interferon alpha for the adjuvant treatment of cutaneous melanoma IRF7: activation, regulation, modification and function The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7 Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis The interferon stimulated gene 54 promotes apoptosis IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway What Do We Know about How Hantaviruses Interact with Their Different Hosts?Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists The Roles of RNase-L in Antimicrobial Immunity and the Cytoskeleton-Associated Innate Response Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection Multiple sclerosis-a quiet revolution The regulation of inflammation by interferons and their STATs Differential effects of type I and II interferons on myeloid cells and resistance to intracellular bacterial infections Insights into cytokine-receptor interactions from cytokine engineering Mnk kinase pathway: Cellular functions and biological outcomes Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old players as modulators of the interferon response Toll-like receptors in antiviral innate immunity Innate immune responses in hepatitis C virus infection Autoimmunity and infection in Sjögren's syndrome Deregulation of type I IFN-dependent genes correlates with increased susceptibility to cytomegalovirus acute infection of dicer mutant mice Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection Interferon-inducible antiviral effectors The Cellular Antiviral Protein Viperin Is Attenuated by Proteasome-Mediated Protein Degradation in Japanese Encephalitis Virus-Infected Cells Oncostatin M Enhances the Antiviral Effects of Type I Interferon and Activates Immunostimulatory Functions in Liver Epithelial Cells Antiviral effect of interferon lambda against West Nile virus Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis High efficiency cell-specific targeting of cytokine activity The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections Deacetylation of p53 induces autophagy by suppressing Bmf expression

P2860

Q21090517-D5A44296-DE9B-474C-A227-40DA35DC424F Q21131133-E7DFD639-DE18-45C6-A6A3-3B2E2F4EB51C Q21131160-F6FD30F5-D443-4169-8BF4-E91B4B574AE6 Q21131237-76CAC74B-9430-4635-B999-3CF92A5D0875 Q21195364-549B753F-E3C4-4CC3-BEB4-9F05101C1727 Q24201908-B643CD60-4775-4F07-80CF-DD679F1BA557 Q24299740-1AF0A26F-B2AA-4509-9F8E-F148AAF8F2BE Q24306662-604ABC52-A5D0-4059-9E63-C364E55C7091 Q24315357-F6259B4E-4B68-4896-B654-D1C95F9B2450 Q24321910-9784DD2B-3A7E-4165-9379-17D1B09BF33E Q24337202-38AFEC59-4F06-4A7F-8482-7F15D88CC692 Q24602706-649EF8CB-A4EB-4269-8025-4FBFDB1BDF00 Q26700090-4E8D4D41-BD49-4127-A6E5-045705B894C6 Q26741181-20A8C485-B409-4ED9-BC07-B86255534410 Q26745547-A9562D96-76C8-4627-8BF0-1FCC2ED49C1B Q26772138-C5BFC87C-4078-4D3C-A583-E8ABFF40F7A3 Q26781529-E1628BBC-20BF-44BF-B3BF-51A648EB667A Q26784252-1C2EB5F8-D369-4F7F-A535-35223453CE01 Q26826930-5B631107-5428-443C-B0D5-7E080E1E789F Q26829387-68D3232D-6B50-41D2-8040-9FEB9340F401 Q26849516-1301A2D8-FE84-425A-BB57-272F8784D509 Q26852703-26A416E1-935F-43B0-BE5C-36A35C87E79C Q26865459-B939F462-8745-47EF-A4E6-6CBA74898F81 Q27001020-0F0BDB8C-B7AC-4197-8FDB-73B0E2845DF0 Q27011462-975D27F0-60CF-42A5-B017-9E4DAF3D956F Q27023055-93ADC244-E24F-445F-B361-E89764F49F3E Q27026174-54367982-6A2F-41A4-80D6-4897CD91469D Q27322501-16C6920E-267D-4CAD-9A7E-039A0EEA3859 Q27345078-2DC9CF87-7738-47BA-BDF7-631752A7B042 Q27486790-C175AC09-8DDC-4EAD-89D3-6948C94BE12B Q27487126-9B6E1F73-86D2-434F-A212-73486DBEE658 Q27488206-D33525CF-3024-4E53-B79A-62E3F8DDC681 Q27488713-03052F99-8A7C-4949-ADEC-A42426038FDE Q27671836-67FDBAEE-716B-4D01-9B88-1673196894CC Q27702599-37A3ACFC-AB7A-42AD-909F-B1C3AED9865D Q28245682-A621A766-A963-4869-ADB7-17AC23920A07 Q28305410-78877833-399C-40DF-865F-1C4DD23C50EB Q28476682-73D45B0E-ED22-43AE-AC53-CEE2F95ABD42 Q28481589-0724E416-D22A-4736-ACF8-57894CBC2EE0 Q28510522-C22D04A2-3F54-4C65-BFB6-4A7850FCBDFA

P2860

Interferons at age 50: past, current and future impact on biomedicine

http://www.wikidata.org/entity/Q28259312

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Interferons at age 50: past, current and future impact on biomedicine

@ast

Interferons at age 50: past, current and future impact on biomedicine

@en

Interferons at age 50: past, current and future impact on biomedicine

@nl

type

label

Interferons at age 50: past, current and future impact on biomedicine

@ast

Interferons at age 50: past, current and future impact on biomedicine

@en

Interferons at age 50: past, current and future impact on biomedicine

@nl

prefLabel

Interferons at age 50: past, current and future impact on biomedicine

@ast

Interferons at age 50: past, current and future impact on biomedicine

@en

Interferons at age 50: past, current and future impact on biomedicine

@nl

P1433

Q28259312-2338BD53-06DB-4ADC-8D5E-F684D7AA4E83

P1476

Q28259312-661FD9A6-5BD4-4924-A469-59336FFA57B5

P2093

Q28259312-46DC0D3A-6533-4477-AB3D-1DC60890B18F

Q28259312-5A6C34B7-0284-4A09-8E27-436FDFBB7922

Q28259312-A17AF871-35D6-4A0C-B515-68306B4B352F

Q28259312-CB82CD50-8E4D-4B6C-84A5-63362E70AAE7

Q28259312-E03EE57A-1781-4A49-824E-B9FFFA16F382

P2860

Q28259312-00595A01-E0D0-491E-955B-48C81A353ADD

Q28259312-01CA16C3-858D-4FFB-B067-50499C59D975

Q28259312-2E9ACEA2-A1D7-497E-A408-B8BF38C593A1

Q28259312-3FDEBB0D-E999-4933-9C69-72BBCAFC4003

Q28259312-4946FADF-AAC1-4C47-934C-2AA7C5B4AF1C

Q28259312-501854bd-465f-84c5-e6bd-5273616b49f8

Q28259312-528FBC0E-83E1-4EB6-AA65-98D93150F880

Q28259312-533966DD-9E8E-4634-98B7-6F8ACBEE3FCD

Q28259312-5FEF7A78-2225-4A5F-BAB4-60B4E5156054

Q28259312-8EED865B-B6DE-4436-A70B-AFCBD129ADC6

P2888

Q28259312-CDB5EB70-217F-4AD2-AA6B-B10F820C9FE1

P304

Q28259312-DDC228EA-6350-4251-8D93-27609EFD0A20

P31

Q28259312-0B286CB1-428C-4D1D-BFA2-F6B5E42F844D

P3181

Q28259312-13A9F136-99D8-491C-A344-FFE5807B3076

P356

Q28259312-F4B1313F-9E65-4811-849D-33C26A01C7C2

P407

Q28259312-AD232F7C-B2D8-42E7-8C54-67B77C07A3CA

P433

Q28259312-921F6253-54B6-4B7E-BB01-D4A22BB1E71C

P478

Q28259312-65C8BDB7-865D-4217-97CA-E40670A88165

P50

Q28259312-4121A1A9-65EA-4934-99EC-F52E57002EE2

Q28259312-8969D221-4083-483A-8018-A7639082DD85

P577

Q28259312-50BF5DC3-CF13-40EE-AED5-85DB7D19A702

P698

Q28259312-569DBB52-345D-47D6-894E-170D98A70137

P3181

P356

P1433

Nature Reviews Drug Discovery

P1476

Interferons at age 50: past, current and future impact on biomedicine

@en

P2093

Ernest C Borden

http://www.w3.org/2001/XMLSchema#string

Ganes C Sen

http://www.w3.org/2001/XMLSchema#string

George R Stark

http://www.w3.org/2001/XMLSchema#string

Graham R Foster

http://www.w3.org/2001/XMLSchema#string

Richard M Ransohoff

http://www.w3.org/2001/XMLSchema#string

P2860

Environmental risk factors for multiple sclerosis. Part I: The role of infection

Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds

Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans.

Stat2-dependent regulation of MHC class II expression.

Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells.

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system.

Systemic alpha-interferon therapy of multiple sclerosis.

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.

P2888

P304

975-990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

130710

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRD2422

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Robert H. Silverman

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18049472

http://www.w3.org/2001/XMLSchema#string